|
|
|
|
Keryx Biopharmaceuticals (NASDAQ: KERX) Responds To Erroneous Report About Planned Phase III Study For Patient
Keryx Biopharmaceuticals (NASDAQ: KERX) Responds To Erroneous Report About Planned Phase III Study For Patients With Colorectal Medical Medical Medical Worldwide Search / Oncology hip Funny Useful Websites Compare and save on surgery Medical and ...
|
|
|
GeoVax Labs provides update on vaccine trials progress
- US biopharmaceutical company GeoVax Labs Inc (OTC: GOVX) gave yesterday an update on its vaccine trials progress.CEO Robert McNally said that the HIV/AIDS population continues to grow at an alarming rate, 60,000 new infections annually, and that's just in...
|
|
|
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
BERKELEY, Calif., Feb.9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial of its antibody...
|
|
|
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
(GlobeNewswire via COMTEX) ----XOMA Ltd.(Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial of its antibody candidate,...
|
|
|
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
BERKELEY, Calif., Feb.9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial of its...
|
|
|
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
BERKELEY, Calif., Feb.9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA - News), a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial...
|
|
|
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
BERKELEY, Calif., Feb.9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial of its...
|
|
|
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052
BERKELEY, Calif., Feb.9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial of its...
|
|
|
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
BERKELEY, Calif., Feb.9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq: XOMA), a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial of its...
|
|
|
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
BERKELEY, Calif., Feb.9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq: XOMA), a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial of its...
|
|
|
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
BERKELEY, Calif., Feb.9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA - News), a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial...
|
|
|
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
BERKELEY, Calif., Feb.9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial of its...
|
|
|
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
BERKELEY, Calif., Feb.9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial of its antibody...
|
|
|
BSD Medical Reports Initiation of a Phase III Study on Pancreatic Cancer Using the BSD-2000 Hyperthermia System in Combination with ..
BSD Medical Reports Initiation of a Phase III Study on Pancreatic Cancer Using the BSD-2000 Hyperthermia System in Combination with Chemotherapy Refer to a friend Business Wire 2010 BSD Medical Corporation (NASDAQ:BSDM) reports initiation of a randomized,...
|
|
|
GeoVax Labs, Inc. Begins Enrollment at Final Site for Preventative Vaccine; Next Step Is to Submit IND Application for Therapeutic Vaccine to FDA (AEGiS)
GeoVax Labs, Inc.Begins Enrollment at Final Site for Preventative Vaccine; Next Step Is to Submit IND Application for Therapeutic Vaccine to FDA PRNewswire - February 8, 2010 http://www.aegis.org/news/pr/2010/PR100210.html -- Hires Clinical Research...
|
|
|
GeoVax Labs, Inc. Begins Enrollment At Final Site For Preventative Vaccine; Next Step Is To Submit IND Application For Therapeutic Vaccine To FDA
GeoVax Labs, Inc.(OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, provided an update on its vaccine...
|
|
|
GeoVax Labs, Inc. Begins Enrollment at Final Site for Preventative Vaccine; Next Step Is to Submit IND Application for Therapeutic Vaccine to FDA
ATLANTA, Feb.8 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX.OB) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious...
|
|
|
Stem Cell Therapeutics Corp. Announces the Third and Final Positive Review by the Data Safety and Monitoring Board for the Modified REGENESIS Phase IIb Stroke Trial
(MARKETWIRE via COMTEX) ----Stem Cell Therapeutics Corp.("SCT" or the "Company") (TSX VENTURE: SSS) announced today it has been advised by the Data Safety Monitoring Board ("DSMB") that its third and final regularly scheduled safety analysis has been...
|
|
|
Phase Forwards Q4 sales up 22% but guidance disappoints
Phase Forward, the US-based company specialising in data management solutions for clinical trials and drug safety, hit or exceeded analysts targets for income and sales in the fourth quarter of 2009, with revenues jumping 22% year on year.But the...
|
|
|
Stem Cell Therapeutics Corp. Announces the Third and Final Positive Review by the Data Safety and Monitoring Board for the Modified REGENESIS Phase IIb Stroke Trial
CALGARY, ALBERTA--(Marketwire - Feb.9, 2010) - Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE: SSS) announced today it has been advised by the Data Safety Monitoring Board ("DSMB") that its third and final regularly scheduled safety...
|
|
|
BSD Medical Reports Initiation of a Phase III Study on Pancreatic Cancer Using the BSD-2000 Hyperthermia Syste
SALT LAKE CITY--(EON: Enhanced Online News)--BSD Medical Corporation (NASDAQ:BSDM) reports initiation of a randomized, multicenter Phase III clinical study using the BSD-2000 Hyperthermia System in combination with chemotherapy for the treatment of...
|
|
|
BSD Medical Reports Initiation of a Phase III Study on Pancreatic Cancer Using the BSD-2000 Hyperthermia System in Combination with Chemotherapy
SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (NASDAQ: BSDM) reports initiation of a randomized, multicenter Phase III clinical study using the BSD-2000 Hyperthermia System in combination with chemotherapy for the treatment of pancreatic...
|
|
|
BSD Medical Reports Initiation of a Phase III Study on Pancreatic Cancer Using the BSD-2000 Hyperthermia System in Combination with Chemotherapy
Companies mentioned in this article: BSD Medical Corporation SALT LAKE CITY -- (BUSINESS WIRE) -- BSD Medical Corporation (NASDAQ:BSDM) reports initiation of a randomized, multicenter Phase III clinical study using the BSD-2000 Hyperthermia System...
|
|
|
BSD Medical Reports Initiation of a Phase III Study on Pancreatic Cancer Using the BSD-2000 Hyperthermia Syste
BSD Medical Corporation (NASDAQ:BSDM) reports initiation of a randomized, multicenter Phase III clinical study using the BSD-2000 Hyperthermia System in combination with chemotherapy for the treatment of pancreatic cancer patients after R0/R1...
|
|
|
BSD Medical Reports Initiation of a Phase III Study on Pancreatic Cancer Using the BSD-2000
BusinessWire - BSD Medical Corporation (NASDAQ:BSDM) reports initiation of a randomized, multicenter Phase III clinical study using the BSD-2000 Hyperthermia System in combination with chemotherapy for the treatment of pancreatic cancer patients...
|
